These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
57 related articles for article (PubMed ID: 4005876)
1. Antitumor activity of a benzaldehyde derivative. Kochi M; Isono N; Niwayama M; Shirakabe K Cancer Treat Rep; 1985 May; 69(5):533-7. PubMed ID: 4005876 [TBL] [Abstract][Full Text] [Related]
2. Benzylidene-glucose: no effect after all? Tanum G; Tveit KM; Høst H; Pettersen EO Am J Clin Oncol; 1990 Apr; 13(2):161-3. PubMed ID: 2316482 [TBL] [Abstract][Full Text] [Related]
3. 4,6-Benzylidene-D-glucose, a benzaldehyde derivative that inhibits protein synthesis but not mitosis of NHIK 3025 cells. Pettersen EO; Dornish JM; Rønning OW Cancer Res; 1985 May; 45(5):2085-91. PubMed ID: 3986764 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of benzaldehyde. Kochi M; Takeuchi S; Mizutani T; Mochizuki K; Matsumoto Y; Saito Y Cancer Treat Rep; 1980 Jan; 64(1):21-3. PubMed ID: 6929727 [TBL] [Abstract][Full Text] [Related]
5. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. Zanetta G; Fei F; Mangioni C Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040 [TBL] [Abstract][Full Text] [Related]
6. Effect on cell survival and protein synthesis of benzylidene-glucose (BG) and the deuterated analogue P-1013 in cultured cells. Dunsaed CB; Dornish JM; Oftebro R; Pettersen EO Anticancer Res; 1995; 15(5B):1921-7. PubMed ID: 8572579 [TBL] [Abstract][Full Text] [Related]
8. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154 [TBL] [Abstract][Full Text] [Related]
9. The activity of paclitaxel in gastrointestinal tumors. Ajani JA; Ilson DH; Kelsen DP Semin Oncol; 1995 Oct; 22(5 Suppl 12):46-50; discussion 51-3. PubMed ID: 7481861 [TBL] [Abstract][Full Text] [Related]
10. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587 [TBL] [Abstract][Full Text] [Related]
11. Antitumour effect of benzylidene-glucose (BG) in rats with chemically induced hepatocellular carcinoma. Pettersen EO; Schwarze PE; Dornish JM; Nesland JM Anticancer Res; 1986; 6(2):147-52. PubMed ID: 3707050 [TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971 [TBL] [Abstract][Full Text] [Related]
13. Combined treatment in advanced stages (IIIb-IV) of non-small cell lung cancer. Mariotta S; Sposato B; Li Bianchi E; Fiorucci F; Ricci A; Carbone F; Crescenzi M; Schmid G Eur Rev Med Pharmacol Sci; 2002; 6(2-3):49-54. PubMed ID: 12708610 [TBL] [Abstract][Full Text] [Related]
14. High-dose cisplatin as neoadjuvant organ-preserving chemotherapy for squamous cell carcinoma of the larynx. Lacava JA; Ferreyra R; Leone BA; Losada C; Elem YL; Vallejo CT Cancer J Sci Am; 1996; 2(1):46-51. PubMed ID: 9166498 [TBL] [Abstract][Full Text] [Related]
15. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2. Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901 [TBL] [Abstract][Full Text] [Related]
16. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490 [TBL] [Abstract][Full Text] [Related]
17. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. Kondagunta GV; Drucker B; Schwartz L; Bacik J; Marion S; Russo P; Mazumdar M; Motzer RJ J Clin Oncol; 2004 Sep; 22(18):3720-5. PubMed ID: 15365068 [TBL] [Abstract][Full Text] [Related]
18. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061 [TBL] [Abstract][Full Text] [Related]
19. Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. Stathopoulos GP; Boulikas T; Kourvetaris A; Stathopoulos J Anticancer Res; 2006; 26(2B):1489-93. PubMed ID: 16619562 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of oral topotecan in advanced non-small cell lung cancer. White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]